Defense Supply Center Philadelphia, Attn: DSCP-M Bldg 9-4, 2800 S. 20th Street, Philadelphia, PA 19145-5099

65 -- ACQUISITION OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) SOL SPO200-99-R-1501 DUE 112698 POC Mike McKeown, Contracting Officer 215-737-5746 mmckeown@dscp.dla.mil Fax 215-737-8050 E-MAIL: Mike McKeown, Contract Officer, mmckeown@dscp.dla.mil. The Defense Supply Center Philadelphia (DSCP) intends to issue a solicitation for a "preferred" Selective Serotonin Reuptake Inhibitor (SSRI) for the Department of Defense (DoD) Basic Core Formulary. The product must be FDA approved as of the issuance date of the solicitation. At the time of issuance of this notice, DSCP is aware of only the following SSRIs, as identified in Facts & Comparisons, citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. Prior to issuance of the solicitation, pharmaceutical companies are hereby invited, but not required, to made a presentation about the clinical attributes of their SSRI at the DoD Pharmacoeconomic Center, Fort Sam Houston, Texas, between 19-26 October 1998. Information received during these presentations will assist in identifying the specifications and evaluation factors that will be used to determine the manufacturers that will meet the yet to be defined requirements of the solicitation. One presentation will be scheduled for each SSRI. Eachpresentation will be limited to no more than one hour. Companies may schedule their presentations by contacting MAJ Donald DeGroff at the DoD Pharmacoeconomic Center, (210) 295-9635 or 295-1271. Pharmaceutical companies are encouraged to provide the following information regarding their product: (1) The efficacy of the product in treating depression, preferably in head-to head comparisons with other SSRIs, using intent to treat and per protocol anaylsis; (2) the minimum therapeutic dose in the treatment of depression; (3) the incidence and severity of adverse effects at various dosage levels; (4) the propensity to cause drug interations at various dosage levels as a result of the degree and extent of Cytochrome P-450 (CYP) enzyme system inhibition. The degree of enzyme inhibition describes the relative affinity of a product for a particular CYP enzyme subsystem. The extent of CYP enzyme inhibition refers to the degree of inhibition produced by a product across all of the various subsystems. (5) any other information pertaining to clinically significant differences between the SSRI and other SSRIs. NOTE: The Government may use information provided during the presentations when drafting its solicitation. However, all awards will be based on the offers received in response to the actual solicitation and the evaluation criteria set forth therein. Posted 09/29/98 (W-SN255905). (0272)

Loren Data Corp. http://www.ld.com (SYN# 0221 19981001\65-0001.SOL)